Ondansetron Dosing in Hepatic Impairment
In patients with severe hepatic impairment (Child-Pugh score ≥10), limit ondansetron to a maximum total daily dose of 8 mg. No dose adjustment is required for mild or moderate hepatic impairment.
Dose Recommendations by Child-Pugh Class
Child-Pugh Class A (Mild Impairment)
- No dose adjustment required 1
- Standard dosing applies (8 mg TID for chemotherapy-induced nausea, 16 mg preoperatively for PONV)
Child-Pugh Class B (Moderate Impairment)
- No dose adjustment required 1
- Standard dosing applies
Child-Pugh Class C (Severe Impairment, Score ≥10)
- Maximum 8 mg total daily dose 1
- This represents a significant reduction from standard dosing regimens
Pharmacokinetic Rationale
The dose restriction in severe hepatic impairment is based on substantial pharmacokinetic alterations 2, 3:
- Clearance reduction: Plasma clearance decreases dramatically (96 ml/min in severe impairment vs 478 ml/min in healthy subjects) 3
- Increased exposure: AUC increases approximately 5-fold (1383 ng·ml⁻¹·h vs 279 ng·ml⁻¹·h) 3
- Prolonged half-life: Elimination half-life extends to 21 hours vs 3.6 hours in healthy subjects 3
- Enhanced bioavailability: Oral bioavailability approaches 100% in severe impairment (vs 66% normally) due to reduced first-pass metabolism 2
Recent PBPK modeling confirms that ondansetron exposure in Child-Pugh C patients approximately doubles compared to Child-Pugh A 4.
Clinical Application
For chemotherapy-induced nausea/vomiting in severe hepatic impairment:
- Use 8 mg once daily (rather than the standard 8 mg TID regimen)
- Administer 30 minutes before chemotherapy
For postoperative nausea/vomiting in severe hepatic impairment:
- Use 8 mg once (rather than the standard 16 mg dose)
- Administer 1 hour before anesthesia induction
Important Caveats
- The Child-Pugh score must be calculated accurately (score of 10 or greater defines severe impairment requiring dose reduction) 1
- No renal dose adjustment is needed regardless of kidney function 1
- The 8 mg daily limit applies to the total daily dose, not per-dose administration 1
- Safety data beyond first-day administration in hepatic impairment are limited 1